[ad_1] Novavax Inc. executives slashed their annual sales guidance in half Monday while wildly missing…
Tag:
Vaccines
-
-
STOCK MARKET
Campus COVID-19 vaccine mandates had the biggest impact on colleges with low-income students. Here’s why they were so effective.
by userby user[ad_1] COVID-19 vaccine mandates at colleges were effective in saving lives, especially in colleges that…
-
STOCK MARKET
Moderna and Pfizer to start clinical trials for COVID-19 boosters that target BA.5 ‘in the near future’
by userby user[ad_1] Moderna MRNA, +3.81% and Pfizer PFE, -0.41% have not yet started clinical trials for…
-
STOCK MARKET
Public school districts facing decision over face mask wearing, as BA.5 creates high levels of community transmission
by userby user[ad_1] A growing number of public school districts across the U.S. are reinstating face-mask mandates,…
-
STOCK MARKET
Do kids still get polio vaccines? Is polio airborne? What you need to know
by userby user[ad_1] The New York health department reported the country’s first case of polio in almost…
-
[ad_1] U.S. health regulators have authorized the use of Novavax Inc.’s COVID-19 vaccine, providing a new option that…
-
STOCK MARKET
25 million children at risk of getting dangerous but preventable illnesses amid steep backslide in vaccinations
by userby user[ad_1] The coronavirus pandemic has caused the biggest backslide in childhood vaccinations in about 30…
-
STOCK MARKET
Novavax’s protein-based vaccine approval fails to boost stock as demand for shots and boosters remains low
by userby user[ad_1] U.S. health regulators authorized the use of Novavax Inc.’s COVID-19 vaccine, providing a new option…
-
STOCK MARKET
New omicron variant worries experts as it spreads in India, and Moderna says new booster offers better protection against BA.4 and BA.5
by userby user[ad_1] A new, highly infectious subvariant of omicron is raising concerns among scientists and health…
-
STOCK MARKET
Novavax is part of the FDA’s COVID-19 booster debate, but its vaccine still hasn’t been authorized
by userby user[ad_1] Novavax’s NVAX, +0.61% COVID-19 vaccine candidate played a front-and-center role during this week’s debate…